A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics

As one of the most common malignant tumors in women, the incidence of ovarian cancer is expected to increase year by year. Due to its lack of typical symptoms and effective screening methods, and the characteristics of implantation and distant metastasis, more than 70% of ovarian cancers were in the metastatic stage at the time of diagnosis. In this study, the investigators will collect large samples of tissue from patients with ovarian cancer, conduct multi-omics studies, and mapped the characteristic maps of the genome and transcriptome of patients with metastatic ovarian cancer, and explore the molecular mechanisms that can be used as new targets for the treatment of ovarian cancer. Besides, the investigators will design and establish a database of metastatic ovarian cancer, integrate multiple omics, imaging, pathology, and clinical information to study their potential relevance, and analyze the relationship between various omics, imaging, pathology, and prognosis, establish ovaries Cancer prediction model.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Ovarian Cancer Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Neoplasms Neoplasms by Site Ovarian Diseases Ovarian Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

The Sun Yat-Sen Memorial Hospital of Sun Yat-Sen Universit

Guangzhou, Guangdong, China

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

female, ≥18 years old;
diagnosed as ovarian cancer by imaging and pathology;
did not receive any anti-tumor drug treatment before surgery in the gynecology clinical department of the Sun Yat Sen Memorial Hospital of Sun Yat-Sen University;
received ovarian cancer surgery and Follow-up treatment;
Patients voluntarily participate in the research of this subject, have good compliance, and can complete the enrollment by the requirements of the trial;
Sign informed consent and agree to the collection and use of their data.

Exclusion criteria

Patients who have received other anti-tumor treatments or received tumor surgery before enrollment;
Patients with malignant tumors in other parts;
Patients with uncontrollable neurological, psychiatric, or mental disorders;
Poor compliance and inability to Cooperate and describe treatment responders.

Treatment and study plan

Primary outcomes

Progression-Free-Survival

Time frame: The sample will be tested immediately after they are taken from patients and the statistical analysis will be taken through study completion, an average of 3 year

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2026
First posted: Feb 23, 2022
Registry last updated: May 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting